Antibiotic macrocyclic peptides

Novel peptide macrocycles effectively target MDR Acinetobacter baumannii, offering a solution to the challenge of antibiotic resistance in treating infections caused by this pathogen.

WO2026233899A1PCT designated stage Publication Date: 2026-11-12F HOFFMANN LA ROCHE & CO AG +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/062746
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-06
Filing Date
2026-05-04
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

There is a high unmet medical need for compounds effective against Multi-Drug Resistant (MDR) Acinetobacter baumannii infections, particularly carbapenem-resistant strains, due to their resistance to most available antimicrobial agents, leading to high mortality and morbidity in healthcare settings.

Method used

Development of novel peptide macrocycles, including compounds of formula (I) and their pharmaceutically acceptable salts, which exhibit high activity against Acinetobacter baumannii, including MDR strains.

Benefits of technology

The novel peptide macrocycles provide effective treatment options for Acinetobacter baumannii infections, addressing the challenge of antibiotic resistance and reducing morbidity and mortality associated with MDR strains.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure EP2026062746_12112026_PF_FP_ABST
    Figure EP2026062746_12112026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention provides compounds of formula (I) [Formula should be inserted here] wherein Y, R1, R2, R3, R4, m, and n are as described herein, as well as pharmaceutically acceptable salts thereof. Further, the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by bacteria.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Case P60149

[0002] Antibiotic Macrocyclic Peptides

[0003] Field of the Invention

[0004] The present invention provides compounds which exhibit activity against bacteria, in particular against Gram-negative bacteria like Acinetobacter baumannii, their manufacture, pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by bacteria.

[0005] Background of the Invention

[0006] Acinetobacter baumannii is a Gram-negative, aerobic, nonfermenting bacterium recognized over the last decades as an emerging pathogen with very limited treatment options.

[0007] A. baumannii is considered to be a serious threat by the US Centers for Disease Control and Prevention and belongs to the so called ‘ESKAPE’ pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter species & E. coli) that currently cause the majority of nosocomial infections and effectively “escape” the activity of antimicrobial agents.

[0008] A. baumannii is most often encountered in intensive care units and surgical wards, where extensive antibiotic use has enabled selection for resistance against all known antimicrobials and where it causes infections that include bacteremia, pneumonia, meningitis, urinary tract infection, and wound infection.

[0009] A. baumannii has an exceptional ability to upregulate and acquire resistance determinants and shows an environmental persistence that allows its survival and spread in the nosocomial setting, making this organism a frequent cause of outbreaks of infection and an endemic, health care-associated pathogen.

[0010] Due to increasing antibiotic resistance to most if not all available therapeutic options, Multi-Drug Resistant (MDR) A. baumannii infections, especially those caused by carbapenem resistant A. baumannii (CRAB), are extremely difficult or even impossible to treat with high mortality rate as well as increased morbidity and length of stay in intensive care unit.

[0011] CNE / 02.04.2026Acinetobacter baumannii has been defined and still remains “a prime example of a mismatch between unmet medical needs and the current antimicrobial research and development pipeline” according to the Antimicrobial Availability Task Force (AATF) of the Infectious Diseases Society of America (IDSA). Thus, there is a high demand and need to identify compounds suitable for the treatment of diseases and infections caused by Acinetobacter baumannii.

[0012] WO2017 / 072062, WO2019185572, and WO2019206853 disclose peptide macrocycles that are active against Acinetobacter baumannii. However, there is still a high unmet medical need for further compounds that are suitable for the treatment of diseases and infections caused by Acinetobacter baumannii, for example in order to overcome potential future resistances to the antibiotic compounds disclosed in the prior art.

[0013] Summary of the Invention

[0014] The present invention provides novel peptide macrocycles that are highly active against Acinetobacter baumannii, including against MDR strains of Acinetobacter baumannii.

[0015] More particularly, in a first aspect, the present invention provides a compound of formula (I)

[0016]

[0017] or a pharmaceutically acceptable salt thereof, wherein Y, R1, R2, R3, R4, m, and n are as described herein.The present invention further provides processes for manufacturing the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by certain bacteria.

[0018] Detailed description of the invention

[0019] Definitions

[0020] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, suitable methods and materials are described below.

[0021] Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein, unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract and drawings), and / or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features and / or steps are mutually exclusive. The invention is not restricted to the details of any foregoing embodiments. The invention extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.

[0022] All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety.

[0023] The nomenclature used in this Application is based on IUPAC systematic nomenclature, unless indicated otherwise. Biovia Draw 24.1 was employed to generate IUPAC chemical names.

[0024] Any open valency appearing on a carbon, oxygen, sulfur or nitrogen atom in the structures herein indicates the presence of a hydrogen atom, unless indicated otherwise.The term “pharmaceutically acceptable salts” denotes salts which are not biologically or otherwise undesirable. Pharmaceutically acceptable salts include both acid and base addition salts. Acid addition salts are those pharmaceutically acceptable salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, carbonic acid, phosphoric acid, and organic acids selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic classes of organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, gluconic acid, lactic acid, pyruvic acid, oxalic acid, malic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, aspartic acid, ascorbic acid, glutamic acid, anthranilic acid, benzoic acid, cinnamic acid, mandelic acid, embonic acid, phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, and salicyclic acid. Base addition salts are those pharmaceutically acceptable salts formed with an organic or inorganic base. Examples of acceptable inorganic bases include sodium, potassium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, and aluminum salts. Salts derived from pharmaceutically acceptable organic nontoxic bases includes salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2-diethylaminoethanol, tromethamine, dicyclohexylamine, lysine, arginine, histidine, procaine, hydrabamine, ethylenediamine, glucosamine, methylglucamine, purines, piperazine, piperidine, N-ethylpiperidine, and polyamine resins.

[0025] The term “parent compound” as used herein refers to compounds of the invention in a zwitterionic (“internal salt”) state.

[0026] Stereochemical definitions and conventions used herein generally follow S. P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., “Stereochemistry of Organic Compounds”, John Wiley & Sons, Inc., New York, 1994. In describing an optically active compound, the prefixes D and L, or R and S, are used to denote the absolute configuration of the molecule about its chiral center(s). The substituents attached to the chiral center under consideration are ranked in accordance with the Sequence Rule of Cahn, Ingold and Prelog. (Cahn et al. Angew. Chem. Inter. Edit. 1966, 5, 385; errata 511). The prefixes D and L or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or L designating that the compound is levorotatory. A compound prefixed with (+) or D is dextrorotatory.The term “halo”, “halogen”, and “halide” are used interchangeably herein and denote fluoro, chloro, bromo, or iodo. Particular examples of halogen are fluoro, chloro, and bromo.

[0027] The term “cyano” refers to a group -CN, i.e., a nitrile group.

[0028] The term “amino” refers to a group –NH2.

[0029] The term “hydroxy” refers to a group -OH.

[0030] The term “carboxy” refers to a group -COOH.

[0031] The term “alkyl” denotes a monovalent linear or branched saturated hydrocarbon group of 1 to 6 carbon atoms (“C1-6-alkyl”). In particular embodiments, alkyl has 1 to 4 carbon atoms, and in more particular embodiments 1 to 3 carbon atoms, for example 1, 2, or 3 carbon atoms.

[0032] Examples of alkyl include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl. A particular, yet non-limiting example of alkyl is methyl.

[0033] The term “alkynyl” denotes a monovalent linear or branched unsaturated hydrocarbon group containing at least one carbon-carbon triple bond, and having 2 to 6 carbon atoms (“C2-6-alkynyl”). In particular embodiments, alkynyl has 2 to 4 carbon atoms, and in more particular embodiments 2 or 3 carbon atoms. Examples of alkynyl include, but are not limited to, ethynyl, propynyl (propargyl), 1-butynyl, and 2-butynyl. A particular, yet non-limiting example of alkynyl is ethynyl.

[0034] The term “alkoxy” refers to an alkyl group, as previously defined, attached to the parent molecular moiety via an oxygen atom. Unless otherwise specified, the alkoxy group contains 1 to 6 carbon atoms (“Ci-6-alkoxy”). In some embodiments, the alkoxy group contains 1 to 4 carbon atoms, e.g., 1, 2, 3, or 4 carbon atoms. In other embodiments, the alkoxy group contains 1 to 3 carbon atoms. Some non-limiting examples of alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy and tert-butoxy. Particular, yet non-limiting examples of alkoxy are methoxy and ethoxy.

[0035] The term “haloalkyl” refers to an alkyl group as defined herein, wherein at least one of the hydrogen atoms of the alkyl group has been replaced by a halogen atom, preferably fluoro. Preferably, “haloalkyl” refers to an alkyl group wherein 1, 2 or 3 hydrogen atoms of the alkyl group have been replaced by a halogen atom, most preferably fluoro. Some non-limiting examples of haloalkyl include trifluoromethyl (CF3), difluoromethyl (CHF2), 1,1-difluoroethyl,2,2-difluoroethyl, and 2,2,2-trifluoroethyl. Particular, yet non-limiting examples of haloalkyl are trifluoromethyl (CF3) and difluoromethyl (CHF2).

[0036] The term "aryl" refers to a monocyclic, bicyclic, or tricyclic carbocyclic ring system having a total of 6 to 10 ring members (“Ce-Cio-aryl”), wherein at least one ring in the system is aromatic. Some non-limiting examples of aryl include phenyl and 9H-fluorenyl (e.g. 9H-fluoren-9-yl). A particular example of aryl is phenyl.

[0037] The term “heterocycloalkyl” refers to a saturated or partly unsaturated monocyclic, bicyclic or tricyclic ring system of 3 to 14 ring atoms, for example 3 to 10 ring atoms, 3 to 8 ring atoms, 3 to 7 ring atoms, 3 to 6 ring atoms, 4 to 6 ring atoms, or 5 to 6 ring atoms, wherein 1-4, for example 1, 2, 3, or 4 of said ring atoms are heteroatoms selected from N, O and S, the remaining ring atoms being carbon. In some instances, the heterocycloalkyl is monocyclic or bicyclic. In some instances, the heterocycloalkyl is monocyclic. The term “bicyclic heterocycloalkyl” refers to heterocycloalkyl moieties consisting of two cycles having two ring atoms in common, i.e., the bridge separating the two rings is either a single bond or a chain of one or two ring atoms, and to spirocyclic moieties, i.e., the two rings are connected via one common ring atom. Some non-limiting examples of heterocycloalkyl groups include aziridinyl, azetidinyl, piperidyl, pyrrolidinyl, oxetanyl, piperidyl, 1,2-dihydropyridyl, piperidyl, pyrrolidinyl, tetrahydrothiophenyl, thietanyl, tetrahydrofuranyl, 3-azabicyclo[3.1.0]hexanyl, 2,5-diazabicyclo[2.2.1]heptanyl, and l-azaspiro[3.3]heptanyl. A particular, yet non-limiting example of heterocycloalkyl includes 1,2-dihydropyridyl.

[0038] The term "heteroaryl" refers to a monocyclic, bicyclic, or tricyclic ring system having a total of 5 to 14 ring atoms, for example 5 to 12 ring atoms, 5 to 10 ring atoms, or 5 to 6 ring atoms, wherein at least one ring in the system is aromatic, and wherein 1-4, for example 1, 2, 3, or 4 of said ring atoms are heteroatoms selected from N, O and S, the remaining ring atoms being carbon. In some instances, the heteroaryl is monocyclic or bicyclic. In some instances, the heteroaryl is monocyclic. Some non-limiting examples of heteroaryl include pyridyl, indolyl, benzoxazolyl, indazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, tetrazolyl, 1,2,4-oxadiazolyl, pyrimidinyl, and 2,3-dihydro-l,4-benzodioxinyl. In some instances, “heteroaryl” refers to pyridyl, indolyl, indazolyl, pyrimidinyl or 2,3-dihydro-l,4-benzodioxinyl. A particular, yet nonlimiting example of “heteroaryl” includes pyridyl.The term “protecting group” denotes the group which selectively blocks a reactive site in a multifunctional compound such that a chemical reaction can be carried out selectively at another unprotected reactive site in the meaning conventionally associated with it in synthetic chemistry. Protecting groups can be removed at the appropriate point. Exemplary protecting groups are amino-protecting groups, carboxy -protecting groups or hydroxy-protecting groups, as can be found, for example, in T. W. Greene and P. G. M. Wuts, “Protective groups in Organic Synthesis”, 2nd ed., John Wiley & Sons, Inc., New York, NY, 1991, chapter 7; E. Haslam, “Protecting groups in Organic Chemistry”, J. G. W. McOmie, Ed., Plenum Press, New York, NY, 1973, Chapter 5, and T. W. Greene, “Protective groups in Organic Synthesis”, John Wiley and Sons, New York, NY, 1981.

[0039] The terms “pharmaceutical composition” and “pharmaceutical formulation” (or “formulation”) are used interchangeably and denote a mixture or solution comprising a therapeutically effective amount of an active pharmaceutical ingredient together with pharmaceutically acceptable excipients to be administered to a mammal, e.g., a human in need thereof.

[0040] The term “pharmaceutically acceptable” denotes an attribute of a material which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and neither biologically nor otherwise undesirable and is acceptable for veterinary as well as human pharmaceutical use.

[0041] The terms “pharmaceutically acceptable excipient”, “pharmaceutically acceptable carrier” and “therapeutically inert excipient” can be used interchangeably and denote any pharmaceutically acceptable ingredient in a pharmaceutical composition having no therapeutic activity and being non-toxic to the subject administered, such as disintegrators, binders, fillers, solvents, buffers, tonicity agents, stabilizers, antioxidants, surfactants, carriers, diluents or lubricants used in formulating pharmaceutical products.

[0042] The term “therapeutically effective amount” denotes an amount of a compound or molecule of the present invention that, when administered to a subject, (i) treats or prevents the particular disease, condition or disorder, (ii) attenuates, ameliorates or eliminates one or more symptoms of the particular disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of the particular disease, condition or disorder described herein. The therapeutically effective amount will vary depending on the compound, the disease state beingtreated, the severity of the disease treated, the age and relative health of the subject, the route and form of administration, the judgement of the attending medical or veterinary practitioner, and other factors.

[0043] The term “treating” or “treatment” of a disease state includes inhibiting the disease state, i.e., arresting the development of the disease state or its clinical symptoms, or relieving the disease state, i.e., causing temporary or permanent regression of the disease state or its clinical symptoms.

[0044] Compounds of the Invention

[0045] In a first aspect, the present invention provides a compound of formula (I)

[0046]

[0047] or a pharmaceutically acceptable salt thereof, wherein:

[0048] Y is CH or N;

[0049] m is an integer selected from the group consisting of 1, 2, and 3;

[0050] n is an integer selected from the group consisting of 1, 2, and 3;

[0051] R1, R2, and R3are each independently selected from the group consisting of hydrogen, halogen, cyano, C1-6-alkyl, C2-6-alkynyl, C6-10-aryl, 5- to 14-membered heteroaryl, and 3- to 14-membered heterocycloalkyl; wherein said C6-10-aryl and 5- to 14- membered heteroaryl are optionally substituted with 1-3 substituents independently selected from the group consisting of hydroxy, halogen, cyano, C1-6-alkyl, Ci-6-aloxy, and carboxy; and wherein said 3- to 14-membered heterocycloalkyl is optionally substituted with 1-3 substituents independently selected from the group consisting of oxo, hydroxy, halogen, cyano, C1-6-alkyl, Ci-6-aloxy, and carboxy; andR4is selected from the group consisting of hydrogen, halogen, C1-6-alkyl, and halo-Ci-6- alkyl;

[0052] wherein said heteroaryl and said heterocycloalkyl comprise 1-4 heteroatoms selected from N, O and S, the remaining ring atoms being carbon.

[0053] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is a compound of formula (la):

[0054]

[0055] wherein the variables are as defined in claim 1.

[0056] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein m is 2 and n is 3.

[0057] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein Y is N.

[0058] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is a compound of formula (lb):

[0059]

[0060] wherein the variables are as defined in claim 1.

[0061] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

[0062] R1is selected from the group consisting of hydrogen, halogen, cyano, C1-6-alkyl, C2-6- alkynyl, C6-10-aryl, 5- to 14-membered heteroaryl, and 3- to 14-membered heterocycloalkyl; wherein said C6-10-aryl and 5- to 14-membered heteroaryl are optionally substituted with 1-3 substituents independently selected from the group consisting of hydroxy, halogen, cyano, C1-6-alkyl, Ci-6-aloxy, and carboxy; and wherein said 3- to 14-membered heterocycloalkyl is optionally substituted with 1-3 substituents independently selected from the group consisting of oxo, hydroxy, halogen, cyano, C1-6-alkyl, Ci-6-aloxy, and carboxy;

[0063] R2is selected from the group consisting of hydrogen, halogen, and C1-6-alkyl; and R3is selected from the group consisting of hydrogen and halogen.

[0064] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

[0065] R1is selected from the group consisting of hydrogen, halogen, C1-6-alkyl, C2-6-alkynyl, C6-10-aryl, 5- to 14-membered heteroaryl, and 3- to 14-membered heterocycloalkyl; wherein said C6-10-aryl is optionally substituted with 1 substituent selected from the group consisting of hydroxy, Ci-6-aloxy, and carboxy; and wherein said 3- to 14- membered heterocycloalkyl is substituted with oxo and optionally 1 C1-6-alkyl substituent;

[0066] R2is selected from the group consisting of hydrogen, halogen, and C1-6-alkyl; andR3is selected from the group consisting of hydrogen and halogen.

[0067] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

[0068] R1is selected from the group consisting of hydrogen, fluoro, chloro, iodo, methyl, ethynyl, phenyl, pyridyl, and 1,2-dihydropyridyl; wherein said phenyl is optionally substituted with 1 substituent selected from the group consisting of hydroxy, methoxy, and carboxy; and wherein said 1,2-dihydropyridyl is substituted with oxo and optionally 1 methyl substituent;

[0069] R2is selected from the group consisting of hydrogen, fluoro, chloro, iodo, and methyl;

[0070] and

[0071] R3is selected from the group consisting of hydrogen, fluoro, chloro, and iodo.

[0072] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

[0073] R1is selected from the group consisting of halogen, C1-6-alkyl, and C6-10-aryl;

[0074] R2is selected from the group consisting of hydrogen and halogen; and

[0075] R3is hydrogen.

[0076] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein:

[0077] R1is selected from the group consisting of iodo, methyl, and phenyl;

[0078] R2is selected from the group consisting of hydrogen and iodo; and

[0079] R3is hydrogen.

[0080] In one embodiment, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, wherein R4is hydrogen.

[0081] In one embodiment, the present invention provides a compound of formula (I) as described herein, selected from the group consisting of:

[0082] 4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[(3-iodophenyl)methyl]-16- methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentazatricyclo[19.4.0.03’8]pentacosa- 1 (25), 3 (8), 4, 6, 21,23 -hexaen-22-yl]benzoic acid;4-[(l IS, 14S,17S)- 14-(4- Aminobutyl)- 11 -(3 -aminopropyl)- 17-benzyl-16-m ethyl- 12, 15,18-tri oxo- 2-thia-4,l 0,13, 16, 19-pentazatri cyclofl 9.4.0.03,8]pentacosa- 1(25), 3(8), 4, 6, 21, 23-hexaen-22- yl]benzoic acid;

[0083] 4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[(3-bromophenyl)methyl]-16- methyl- 12, 15,18-tri oxo-2-thia-4,l 0,13, 16, 19-pentazatri cyclofl 9.4.0.03,8]pentacosa- 1 (25), 3 (8), 4, 6, 21,23 -hexaen-22-yl]benzoic acid;

[0084] 4-[(l lS,14S,17S)-14-(4-Aminobutyl)-l l-(3-aminopropyl)-17-[(5-chloro-2-methyl- phenyl)m ethyl]- 16-methyl- 12,15,18-tri oxo-2-thia-4, 10,13,16,19- pentazatricyclo[19.4.0.03’8]pentacosa-l(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid;

[0085] 4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[(3-chlorophenyl)methyl]-16- methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentazatricyclo[19.4.0.03’8]pentacosa- 1 (25), 3 (8), 4, 6, 21,23 -hexaen-22-yl]benzoic acid;

[0086] 4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[(2-iodophenyl)methyl]-16- methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentazatricyclo[19.4.0.03’8]pentacosa- 1 (25), 3 (8), 4, 6, 21,23 -hexaen-22-yl]benzoic acid;

[0087] 4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[(5-iodo-2-phenyl-phenyl)methyl]- 16-methyl- 12, 15,18-tri oxo-2 -thia-4, 10, 13, 16, 19-pentazatri cyclofl 9.4.0.03,8]pentacosa- 1 (25), 3 (8), 4, 6, 21,23 -hexaen-22-yl]benzoic acid;

[0088] 4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[(5-iodo-2,4-dimethyl- phenyl)m ethyl]- 16-methyl- 12,15,18-tri oxo-2 -thia-4, 10,13,16,19- pentazatricyclo[19.4.0.03’8]pentacosa-l(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid;

[0089] 4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[(4-fluoro-3-iodo-phenyl)methyl]- 16-methyl- 12, 15,18-tri oxo-2 -thia-4, 10, 13, 16, 19-pentazatri cyclofl 9.4.0.03,8]pentacosa- l(21),3(8),4,6,22,24-hexaen-22-yl]benzoic acid;

[0090] 4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[(5-iodo-2-methyl- phenyl)m ethyl]- 16-methyl- 12,15,18-tri oxo-2 -thia-4, 10,13,16,19- pentazatricyclo[19.4.0.03’8]pentacosa-l(21),3(8),4,6,22,24-hexaen-22-yl]benzoic acid;

[0091] 4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[(4-iodophenyl)methyl]-16- methyl- 12, 15,18-tri oxo-2-thia-4,l 0,13, 16, 19-pentazatri cyclofl 9.4.0.03,8]pentacosa- 1 (25), 3 (8), 4, 6, 21,23 -hexaen-22-yl]benzoic acid;

[0092] 4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[(3-ethynylphenyl)methyl]-16- methyl- 12, 15,18-tri oxo-2-thia-4,l 0,13, 16, 19-pentazatri cyclofl 9.4.0.03,8]pentacosa- l(21),3(8),4,6,22,24-hexaen-22-yl]benzoic acid;4-[(l lS,14S,17S)-14-(4-Aminobutyl)-l l-(3-aminopropyl)-17-[(2-bromo-5-chloro- phenyl)m ethyl]- 16-methyl- 12,15,18-trioxo-2-thia-4, 10,13,16,19- pentazatricyclo[19.4.0.03’8]pentacosa-l(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid;

[0093] 4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[[2-(4-carboxyphenyl)-5-chloro- phenyl]methyl]- 16-methyl- 12,15,18-trioxo-2-thia-4, 10,13,16,19- pentazatricyclo[19.4.0.03’8]pentacosa-l(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid;

[0094] 4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[(5-chloro-2-phenyl- phenyl)m ethyl]- 16-methyl- 12,15,18-trioxo-2-thia-4, 10,13,16,19- pentazatricyclo[19.4.0.03’8]pentacosa-l(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid;

[0095] 3-[2-[[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-22-(4-carboxyphenyl)-16-methyl- 12,15,18-trioxo-2-thia-4,10,13,16,19-pentazatricyclo[19.4.0.03’8]pentacosa- l(25),3(8),4,6,21,23-hexaen-17-yl]methyl]-4-chloro-phenyl]benzoic acid;

[0096] 4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[[5-chloro-2-(2- methoxyphenyl)phenyl]methyl]- 16-methyl- 12,15,18-trioxo-2-thia-4, 10,13,16,19- pentazatricyclo[19.4.0.03’8]pentacosa-l(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid;

[0097] 4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[[5-chloro-2-(4- pyridyl)phenyl]methyl]- 16-methyl- 12,15,18-trioxo-2-thia-4, 10,13,16,19- pentazatricyclo[19.4.0.03’8]pentacosa-l(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid;

[0098] 4-[(l lS,14S,17S)-14-(4-Aminobutyl)-l l-(3-aminopropyl)-17-[[5-chloro-2-(2-oxo-lH-pyridin-3- yl)phenyl]methyl]- 16-methyl- 12,15,18-trioxo-2-thia-4, 10,13,16,19- pentazatricyclo[19.4.0.03’8]pentacosa-l(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid;

[0099] 4-[(l lS,14S,17S)-14-(4-Aminobutyl)-l l-(3-aminopropyl)-17-[[5-chloro-2-(l-methyl-2-oxo-3- pyridyl)phenyl]methyl]- 16-methyl- 12,15,18-trioxo-2-thia-4, 10,13,16,19- pentazatricyclo[19.4.0.03’8]pentacosa-l(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid;

[0100] 4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[[5-chloro-2-(2- hydroxyphenyl)phenyl]methyl]- 16-methyl- 12,15,18-trioxo-2-thia-4, 10,13,16,19- pentazatricyclo[19.4.0.03’8]pentacosa-l(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid;

[0101] 4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[[5-chloro-2-(2- pyridyl)phenyl]methyl]- 16-methyl- 12,15,18-trioxo-2-thia-4, 10,13,16,19- pentazatricyclo[19.4.0.03’8]pentacosa-l(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid; and 4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[[5-chloro-2-(3- pyridyl)phenyl]methyl]- 16-methyl- 12,15,18-trioxo-2-thia-4, 10,13,16,19- pentazatricyclo[19.4.0.03’8]pentacosa-l(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid;or a pharmaceutically acceptable salt thereof.

[0102] In one embodiment, the present invention provides pharmaceutically acceptable salts of the compounds according to formula (I) as described herein, especially hydrochloride salts, more particularly dihydrochloride salts. In a further particular embodiment, the present invention provides compounds according to formula (I) as described herein as internal salts (zwitterions).

[0103] In some embodiments, the compounds of formula (I) are isotopically-labeled by having one or more atoms therein replaced by an atom having a different atomic mass or mass number. Such isotopically-labeled (i.e., radiolabeled) compounds of formula (I) are considered to be within the scope of this disclosure. Examples of isotopes that can be incorporated into the compounds of formula (I) include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, chlorine, and iodine, such as, but not limited to,2H,3H,11C,13C,14C,13N,15N,15O,17O,18O,32P,33P,35S,18F,36C1,123I, and125I, respectively. Certain isotopically-labeled compounds of formula (I), for example, those incorporating a radioactive isotope, are useful in drug and / or substrate tissue distribution studies. The radioactive isotopes tritium, i.e.3H, and carbon-14, i.e.,14C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection. For example, a compound of formula (I) can be enriched with 1, 2, 5, 10, 25, 50, 75, 90, 95, or 99 percent of a given isotope.

[0104] Substitution with heavier isotopes, such as deuterium, i.e.2H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements. Therefore, deuterated versions of the compounds disclosed herein are to be understood to be within the scope of the present invention. For example, compounds of formula (I) wherein 1-6 hydrogen atoms, for example 1, 2, 3, 4, 5 or 6 hydrogen atoms, are replaced with deuterium atoms are understood to be within the scope of the present invention.

[0105] Substitution with positron emitting isotopes, such as11C,18F,15O and13N, can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.

[0106] Isotopically-labeled compounds of formula (I) can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the Examples as set out below using an appropriate isotopically-labeled reagent in place of the nonlabeled reagent previously employed.Manufacturing Processes

[0107] The compounds of the present invention can be prepared by any conventional means. Suitable processes for synthesizing these compounds as well as their starting materials are provided in the schemes below and in the examples. All substituents, in particular R1R2, R3, R4, m, n, and Y are as defined above unless otherwise indicated. Furthermore, and unless explicitly otherwise stated, all reactions, reaction conditions, abbreviations and symbols have the meanings well known to a person of ordinary skill in organic chemistry.

[0108] 1. General synthesis of the aldehyde intermediate

[0109] The aldehyde intermediate of formula (II) can be prepared following standard methods known in the art, particularly according to methods as described in the examples.

[0110]

[0111] In compound (II), PG is a suitable amino protecting group, such as 9-fluorenylmethoxy-carbonyl, Y and R4are as defined herein.

[0112] 2. General synthesis of the tripeptide

[0113] The tripeptide of formula (III), wherein R1, R2and R3are as defined herein, can be prepared following standard methods known in the art.

[0114]

[0115] The tripeptide (III) can for example be synthesized from dipeptide (IV) and N-methylphenylalanine derivative (V) as follows (PG is a suitable protective group, e. g., 9-fluorenylmethoxycarbonyl, Rais lower alkyl, preferably methyl or allyl, m, n, R1, R2and R3are as defined above):

[0116]

[0117] (IV) (v)

[0118] a) In the first step, dipeptide (IV) is reacted with N-methylphenylalanine derivative (V) in an amide coupling reaction, using reagents and methods known in the art. For instance, the reaction is performed in the presence of N, N’-diisopropyl- carbodiimide and either 1-hydroxy-7-azabenzotriazole or 2-hydroxypyridine-N- oxide in a suitable solvent, e. g., dichloromethane, tetrahydrofuran, tert-butyl- methyl ether or N, N-dimethylacetamide, at temperatures between -40°C and +40°C.

[0119] b) In the second step, the protective group (PG) is removed, using methods and reagents known in the art. Suitable reagents for the deprotection reaction are bases such as with a base, preferably a primary or amine such as diethylamine, dicyclohexylamine or tert-amylamine, and the reaction is performed in a suitable solvent, e. g., acetonitrile, at temperatures between -40°C and +50°C. After completion of this step, In a particular embodiment, the N-protected dipeptide is protected with 9-fluorenylmethyloxy carbonyl.

[0120] Dipeptides (IV) are either commercially available or can be produced using procedures known in the art.

[0121] N-Methylphenylalanine derivatives (V) can be produced following standard methods known in the art, particularly according to methods as described in the examples.

[0122] 3. General procedure for the assembly of macrocyclic intermediate (VIII)

[0123] The intermediates of formula (VIII) can be obtained, for example starting from the compounds of formula (II) and of formula (III) according to Scheme 1. PG is a protective group, e. g., 9-fluorenylmethoxycarbonyl, Rais lower alkyl, preferably methyl or allyl, m, n, Y, R1, R2, R3and R4are as defined herein.Scheme 1

[0124]

[0125] In scheme 1, step a, aldehyde of formula (II) is coupled with the tripeptide of formula (III) in a reductive amination reaction, producing intermediate (VI). This reaction is performed e. g., in the presence of a suitable reducing agent, e. g., sodium cyanoborohydride or sodium triacetoxyborohydride, in a solvent like toluene or dichloromethane, in the presence of a carboxylic acid selected from acetic acid and propionic acid, at temperatures between 0°C and 50°C.

[0126] In scheme 1, step b, the amine protective group (PG) and the ester are removed, using methods and reagents known in the art, producing intermediate (VII). In the case where Rais allyl, the reaction can be accomplished in the presence of a palladium catalyst, e. g., tetrakis(triphenylphosphine)palladium(0) and abase, e. g., diethylamine, in a solvent such as acetonitrile, at temperatures between 0°C and 50°C. In the case where Rais methyl, the reaction can be accomplished in the presence of lithium bromide and a base, e. g., diethylamine, in a solvent such as acetonitrile, at temperatures between 0°C and 80°C.In scheme 1, step c, intermediate of formula (VIII) is finally obtained through cyclisation of intermediate (VII) using methods and reagents known in the art. For instance, the reaction is performed in the presence of coupling reagents such as l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride or carbonyldiimidazole, or N, N’ -diisopropylcarbodiimide and 1-hydroxy-7-azabenzotriazole, or 1 -hydroxybenzotriazole and l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, in a solvent such as dichloromethane or N,N-dimethylformamide, at temperatures between -20°C and +40°C.

[0127] 4. General procedure for the cleavage of the protective groups

[0128] In scheme 2, the protecting groups in intermediate (VIII) are cleaved using methods and reagents known in the art, producing compounds of general formula (I). R1, R2, R3, R4, Y, m and n are as defined herein. For instance, a global deprotection can be performed using hydrochloric acid in a suitable solvent or solvent mixture, e. g., 1,4-di oxane, or water / tetrahydrofuran, at temperatures between 0°C and 60°C.

[0129] Scheme 2

[0130]

[0131] Alternatively, the protective groups can be cleaved using trifluoroacetic acid or boron tribromide in dichloromethane at temperatures between -20°C and +40°C, followed by evaporation of the solvent and hydrolysis in water or aqueous hydrochloric acid at room temperature. By this sequence, for example the following protecting groups may be removed:

[0132] • the two tert-butoxycarbonyl groups at the aminoalkyl subunits

[0133] a tert-butyl ester.Pharmaceutical Compositions

[0134] Another aspect of the invention provides pharmaceutical compositions or medicaments comprising the compounds of the invention and a therapeutically inert carrier, diluent or pharmaceutically acceptable excipient, as well as methods of using the compounds of the invention to prepare such compositions and medicaments.

[0135] Compositions are formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.

[0136] The compounds of the invention may be administered by any suitable means, including oral, topical (including buccal and sublingual), rectal, vaginal, transdermal, parenteral, subcutaneous, intraperitoneal, intrapulmonary, intradermal, intrathecal and epidural and intranasal, and, if desired for local treatment, intralesional administration. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration.

[0137] In a preferred embodiment, there is provided a pharmaceutical composition comprising one or more compounds of the invention, wherein said pharmaceutical composition is suitable for intravenous administration.

[0138] The compounds of the present invention may be administered in any convenient administrative form, e.g., tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches, etc. Such compositions may comprise components conventional in pharmaceutical preparations, e.g., diluents, carriers, pH modifiers, preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents, antioxidants, and further active agents. They can also comprise still other therapeutically valuable substances.

[0139] A typical formulation is prepared by mixing a compound of the present invention and a carrier or excipient. Suitable carriers and excipients are well known to those skilled in the art and are described in detail in, e.g., Ansel H. C. et al., Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems (2004) Lippincott, Williams & Wilkins, Philadelphia; Gennaro A. R. et al, Remington: The Science and Practice of Pharmacy (2000) Lippincott, Williams & Wilkins,Philadelphia; and Rowe R. C, Handbook of Pharmaceutical Excipients (2005) Pharmaceutical Press, Chicago. The formulations may also include one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide an elegant presentation of the drug (i.e., a compound of the present invention or pharmaceutical composition thereof) or aid in the manufacturing of the pharmaceutical product (i.e., medicament).

[0140] The dosage at which compounds of the invention can be administered can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case. In general, in the case of intravenous administration a daily dosage of about 1 to 2000 mg per person of a compound of general formula (I) should be appropriate, although the above upper limit can also be exceeded when necessary.

[0141] An example of a suitable intravenous dosage form is a sterile aqueous solution comprising about 1 mg to about 1000 mg of a compound of the invention. Such a sterile aqueous solution for intravenous administration may be obtained e.g. by dissolving about 1 mg to about 1000 mg of a parent compound of the invention in sterile water for injection (SWFI, e.g. about 50 mL) and adjusting the pH to 4-8, preferably around 5 by addition of aqueous hydrochloric acid solution. Alternatively, about 1 mg to about 1000 mg of a pharmaceutically acceptable salt of a compound of the invention, for example of a hydrochloric acid salt, may be dissolved in SWFI, followed by adjusting the pH to 4-8, preferably around 5 by addition of aqueous sodium hydroxide solution. The procedure is completed by terminal sterilization using methods known in the art. In some instances, it may be necessary to add a stabilizer to the final solution to prevent active pharmaceutical ingredient (API) decomposition over time. A suitable stabilizer may be methionine. An exemplary, yet non-limiting intravenous dosage form is as follows:

[0142]

[0143] The sterile aqueous solution may need to be diluted with SWFI prior to intravenous administration. The SWFI may contain 5-10% wt / wt of dextrose and / or 0.9% wt / wt of sodium chloride.

[0144] In one aspect, the present invention provides an aqueous pharmaceutical composition comprising:

[0145] (i) a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof; and

[0146] (ii) methionine.

[0147] An example of an aerosol formulation can be prepared by dissolving the compound, for example 10 to 100 mg, of the invention in a suitable buffer solution, e.g. a phosphate buffer, adding a tonicifier, e.g. a salt such as sodium chloride, if desired. The solution may be filtered, e.g., using a 0.2 μm filter, to remove impurities and contaminants.

[0148] Uses

[0149] The compounds of the present invention exhibit potent and selective antibacterial activity against members of the baumannii-calcoaceticus complex of opportunistic bacterial pathogens. Thus, the compounds of the present invention can be used, either alone or in combination with other drugs, for the treatment of diseases caused by infections with members of said ABC complex of pathogens.

[0150] In one aspect, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, for use as a therapeutically active substance, in particular for use as an antibiotic.

[0151] In one aspect, the present invention provides a method for the treatment of diseases caused by infections with members of the A. baumannii-calcoaceticus complex of pathogens in a subject, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof

[0152] In one embodiment, said diseases caused by infections with members of the A. baumannii-calcoaceticus complex of pathogens are selected from bacteremia, pneumonia, meningitis, urinary tract infection, and wound infection.Members of the A. baumannii-calcoaceticus complex of pathogens are notorious for causing invasive infections in hospitalized patients and patients with critical illness, most commonly hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP) and / or bloodstream infections (BSI). Thus, in a preferred embodiment, said diseases caused by infections with members of the ABC complex of pathogens are selected from HABP, VABP and / or BSI.

[0153] In one embodiment, said member from the A. baumannii-calcoaceticus complex of pathogens is multi drug resistant (MDR).

[0154] In one embodiment, said member from the A. baumannii-calcoaceticus complex of pathogens is Acinetobacter baumannii.

[0155] In a preferred embodiment, said member from the A. baumannii-calcoaceticus complex of pathogens is carbapenem-resistant baumannii (CRAB).

[0156] In one embodiment, said member from the A. baumannii-calcoaceticus complex of pathogens is colistin-resistant and / or polymyxin B-resistant.

[0157] In a preferred embodiment, said member from the A. baumannii-calcoaceticus complex of pathogens is colistin-resistant and / or polymyxin B-resistant CRAB.

[0158] In one embodiment, said member from the A. baumannii-calcoaceticus complex of pathogens is MDR Acinetobacter baumannii.

[0159] In one embodiment, said member from the A. baumannii-calcoaceticus complex of pathogens is colistin-resistant and / or polymyxin B-resistant Acinetobacter baumannii.

[0160] In one embodiment, said subject is a critically ill hospitalized subject with limited treatment options.

[0161] In one embodiment, the present invention provides a method for the treatment of HABP, VABP and / or BSI caused by infections with colistin-resistant and / or polymyxin B-resistant Acinetobacter baumannii in a subject, comprising administering to the subject a therapeutically effective amount of a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereofIn one embodiment, the present invention provides a method for the treatment of HABP, VABP and / or BSI caused by infections with colistin-resistant and / or polymyxin B-resistant Acinetobacter baumannii in a critically ill hospitalized subject with limited treatment options, comprising administering to the critically ill hospitalized subject with limited treatment options a therapeutically effective amount of a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof

[0162] In one aspect, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, for use in a method of treatment described herein.

[0163] In one aspect, the present invention provides the use of a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, in a method of treatment described herein.

[0164] In one aspect, the present invention provides a compound of formula (I) as described herein, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of diseases caused by bacterial infections as described herein.

[0165] Examples

[0166] The invention will be more fully understood by reference to the following examples. They should however not be construed as limiting the scope of the invention.

[0167] All examples and intermediates were prepared under nitrogen atmosphere if not specified otherwise.

[0168] Abbreviations used

[0169] Abbreviations: aq. = aqueous; Boc = tert-butoxycarbonyl; DMSO = dimethyl sulfoxide; MS = mass spectrometry; HPLC = high-performance liquid chromatography; NMR = nuclear magnetic resonance spectroscopy; CAS-RN = Chemical Abstracts Service Registry Number.

[0170] Intermediates

[0171] Intermediate 1

[0172] tert-Butyl 4-[2-[(9H-fluoren-9-ylmethoxycarbonylamino)methyl]-3-[(3-formyl-2-pyridyl)sulfanyl] phenyl] benzoate

[0173]

[0174] To a solution of 9H-fluoren-9-ylmethyl N-[[2-bromo-6-[(3-formyl-2-pyridyl)sulfanyl]-phenyl]methyl]carbamate (CAS-RN 2377676-61-2; 5.00 g, 9.17 mmol) and 4-(tert-butoxycarbonyl)phenylboronic acid (3.05 g, 13.8 mmol) in toluene (50 mL) and water (5 mL) was added tripotassium phosphate (2.92 g, 13.8 mmol) and bis(tri-tert-butylphosphine)palladium(O) (94 mg, 0.18 mmol) in a glovebox at 15°C, then the mixture was stirred at 80°C for 5 h. After cooling the reaction mixture was partitioned between ethyl acetate (50 mL) and brine (50 mL). The organic layer was dried over sodium sulfate, filtered, and evaporated. The residue was purified by chromatography (SiO₂; petroleum ether / ethyl acetate 3:1) to produce the title compound (5.30 g, 89%). Orange solid, MS: 643.2 [M+H]+.

[0175] Intermediate 2

[0176] Allyl (2S)-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]-3-(3-iodophenyl)propanoate

[0177]

[0178] Step 1: 9H-Fluoren-9-ylmethyl (4S)-4-l(3-iodophenyl)methyl1-5-oxo-oxazolidine-3-carboxylate To a solution of N-[(9H-fluoren-9-ylmethoxy)carbonyl]-3-iodo-L-phenylalanine (CAS-RN 210282-31-8; 7.0 g, 13.6 mmol) in toluene (70 mL) was added paraformaldehyde (1.23 g, 13.6 mmol) and trifluoracetic acid (10.1 mL, 136 mmol) at 25°C, then after 16 h the reaction mixture was evaporated. The residue was partitioned between ethyl acetate (90 mL) and saturated aq. sodium hydrogen carbonate solution (90 mL). The organic layer was washed with brine (100 mL), dried over sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by chromatography (Si Ch; petroleum ether / ethyl acetate 2: 1) to produce the title compound (6.5 g, 89%). White solid, MS: 526.1 [M+H]+.

[0179] Step 2: (2S)-2-r9H-Fluoren-9-ylmethoxycarbonyl(methyl)amino1-3-(3-iodophenyl)propanoic acidTo a solution of 9H-fluoren-9-ylmethyl (4S)-4-[(3-iodophenyl)methyl]-5-oxo-oxazolidine-3-carboxylate (6.5 g, 12.4 mmol) in dichloroethane (28 mL) was added triethylsilane (15.8 mL, 99 mmol) and trifluoroacetic (23 mL, 309 mmol). The mixture was stirred at 60°C for 12 h, then concentrated under vacuum. The residue was purified by chromatography (SiO₂; petroleum ether / ethyl acetate 2:1) to produce the title compound (6.3 g, 89%). Brown oil, MS: 550.0 [M+Na]+.

[0180] Step 3: Allyl (2S)-2-19H-fluoren-9-ylmethoxycarbonyl(methyl)amino1-3-(3-iodophenyDpropanoate

[0181] To a solution of (2S)-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]-3-(3-iodophenyl)propanoic acid (4.3 g, 8.15 mmol) in N, N-dimethylformamide (45 mL) was dropwise added diisopropylethylamine (2.13 mL, 12.2 mmol) at 0-5°C, followed by allyl bromide (1.41 mL, 16.3 mmol), then the yellow solution was warmed to 20°C. After 16 h the reaction mixture was partitioned between ethyl acetate (60 mL) and water (40 mL). The organic layer was washed with brine (50 mL), dried over sodium sulfate, filtered, and evaporated. The residue was purified by chromatography (SiO₂; petroleum ether – ethyl acetate gradient) to produce the title compound (4.2 g, 87%). Yellow oil, MS: 590.1 [M+Na]+.

[0182] Step 4: Allyl (2S)-3-(3-iodophenyl)-2-(methylamino)propanoate

[0183] To a solution of allyl (2S)-2-[9H-fluoren-9-ylmethoxycarbonyl(methyl)amino]-3-(3-iodophenyl)propanoate (4.2 g, 7.4 mmol) in acetonitrile (42 mL) was added diethylamine (7.6 mL, 74 mmol) at 25°C, then the reaction mixture was concentrated and the residue was purified by chromatography (SiO₂; dichloromethane – methanol gradient) to produce the title compound (2.3 g, 50%). Yellow oil, MS: 346.1 [M+H]+.

[0184] The following intermediates (Int.) were produced in analogy to intermediate 2, replacing N-[(9H-fluoren-9-ylmethoxy)carbonyl]-3-iodo-L-phenylalanine in step 1 by the appropriate starting material

[0185]

[0186]

[0187] Intermediate 7

[0188] Allyl (2S)-3-(2-bromo-5-chloro-phenyl)-2-(methylamino)propanoate

[0189]

[0190] Step 1: (2S,5R)-2-l(2-Bromo-5-chloro-phenyl)methyl1-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazine

[0191] To a solution of (R)-2,5-dihydro-3,6-dimethoxy-2-isopropylpyrazine (CAS-RN 109838-85-9; 2.00 g, 10.9 mmol) in tetrahydrofuran (20 mL) was added n-butyllithium solution (2.5 M in hexane (4.78 mL, 11.9 mmol) at -70°C, then after 30 min a solution of l-bromo-2-(bromomethyl)-4-chlorobenzene (CAS-RN 66192-24-3; 3.24 g, 11.4 mmol) in tetrahydrofuran (10 mL) was added over 10 min, then after another 3 h the reaction mixture was partitioned between saturated aq. ammonium chloride solution and ethyl acetate. The organic layer was washed with water and brine, dried over sodium sulfate, filtered, and concentrated to produce the title compound (4.20 g, 92%), which was used directly in the next step. Yellow oil, MS: 389.1 [M+H]+.

[0192] Step 2: Methyl (2S)-2-amino-3-(2-bromo-5-chloro-phenyl)propanoateTo a solution of (2S,5R)-2-[(2-bromo-5-chloro-phenyl)methyl]-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazine (4.20 g, 10.8 mmol) in acetonitrile (40 mL) was added 0.6 M aq. hydrochloric acid solution (40 mL, 24 mmol) at 20°C, then after 2 h the pH was adjusted to 8-9 by addition of saturated aq. sodium hydrogen carbonate solution. The reaction mixture was extracted with ethyl acetate, the organic layer was washed with brine (30 mL), dried over sodium sulfate, filtered, and concentrated to produce the title compound (3.30 g, 91%), which was used directly in the next step. Yellow oil, MS: 293.9 [M+H]+.

[0193] Step 3: Methyl (2S)-3-(2-bromo-5-chloro-phenyl)-2-r(2-nitrophenyl)sulfonylamino]propanoate To a suspension of methyl (2S)-2-amino-3-(2-bromo-5-chloro-phenyl)propanoate (1.50 g, 5.13 mmol) in ethyl acetate (15 mL) and water (15 mL) was added potassium carbonate (778 mg, 7.69 mmol) and 2-nitrobenzenesulfonyl chloride (1.25 g, 5.64 mmol) at 20°C, then after 16 h the reaction mixture was partitioned between ethyl acetate (30 mL) and water (15 mL). The organic layer was washed with water (15 mL) and brine (15 mL), dried over sodium sulfate, filtered, and evaporated. The residue was purified by chromatography (SiO₂; petroleum ether / ethyl acetate 2:1) to produce the title compound (900 mg, 29%). Yellow semisolid, MS: 501.0 [M+Na]+. Step 4: Methyl (2S)-3-(2-bromo-5-chloro-phenyl)-2-rmethyl-(2-nitrophenyl)sulfonyl-aminolpropanoate

[0194] To a solution of methyl (2S)-3-(2-bromo-5-chloro-phenyl)-2-[(2-nitrophenyl)sulfonyl-amino]propanoate (500 mg, 1.05 mmol) in ethyl acetate (5 mL) were added potassium carbonate (289 mg, 2.09 mmol) and tetrabutylammonium bromide (34 mg, 0.1 mmol) and iodomethane (0.13 mL, 2.09 mmol) at 25°C. The reaction mixture was heated at 40°C for 3 h, then partitioned between ethyl acetate (20 mL) and water (10 mL). The organic layer was washed with brine (10 mL), dried over sodium sulfate, filtered, and evaporated. The residue was purified by chromatography (SiO₂; petroleum ether / ethyl acetate 2:1) to produce the title compound (360 mg, 69%). Yellow solid, MS: 493.0 [M+H]+.

[0195] Step 5: (2S)-3-(2-Bromo-5-chloro-phenyl)-2-rmethyl-(2-nitrophenyl)sulfonyl-amino]propanoic acid

[0196] To a solution of methyl (2S)-3-(2-bromo-5-chloro-phenyl)-2-[methyl-(2-nitrophenyl)sulfonyl-amino]propanoate (360 mg, 0.73 mmol) in acetonitrile (5.4 mL) was added triethylamine (1.02 mL, 7.32 mmol) and lithium bromide (636 mg, 7.32 mmol) at 25°C. The reaction mixture was heated at 50°C for 16 h, then partitioned between ethyl acetate (20 mL) and 1 M aq. hydrochloric acid solution (20 mL). The organic layer was washed with brine, dried over sodium sulfate,filtered and concentrated to produce the title compound (350 mg, 92%), which was used directly in the next step. Yellow solid, MS: 500.9 [M+Na]⁺. Step 6: Allyl (2S)-3-(2-bromo-5-chloro-phenyl)-2-[methyl-(2-nitrophenyl)sulfonyl-amino]propanoate

[0197] To a solution of (2S)-3-(2-bromo-5-chloro-phenyl)-2-[methyl-(2-nitrophenyl)sulfonyl-amino]propanoic acid (350 mg, 0.73 mmol,) in N, N-dimethylformamide (3.5 mL) was added triethylamine (0.51 mL, 3.66 mmol) and allyl bromide (0.25 mL, 2.93 mmol) at 25°C, then after 16 h the reaction mixture was treated with water (25 mL). The precipitate was collected by filtration and dried to produce the title compound (270 mg, 69%), which was used directly in the next step. Off-white solid, MS: 541.0 [M+H]+.

[0198] Step 7: Allyl (2S)-3-(2-bromo-5-chloro-phenyl)-2-(methylamino)propanoate

[0199] Benzenethiol sodium salt (184 mg, 1.67 mmol) and potassium carbonate (216 mg, 1.56 mmol) were added to a solution of allyl (2S)-3-(2-bromo-5-chloro-phenyl)-2-[methyl-(2-nitrophenyl)sulfonyl-amino]propanoate (270 mg, 0.52 mmol) in N, N-dimethylformamide (3 mL) at -5°C (3 mL). The reaction mixture was stirred at 0°C for 2 h, then partitioned between ethyl acetate (30 mL) and water (10 mL). The organic layer was washed with brine, dried over sodium sulfate, filtered, and evaporated. The residue was purified by chromatography (SiO₂; petroleum ether / ethyl acetate 4:3) to produce the title compound (130 mg, 73%). Yellow oil, MS: 334.0 [M+H]+.

[0200] The following intermediates (Int.) were produced in analogy to intermediate 7, replacing 1-bromo-2-(bromomethyl)-4-chlorobenzene in step 1 by the appropriate benzyl bromide

[0201]

[0202]

[0203] Intermediate 12

[0204] Methyl (2S)-3-[5-chloro-2-(3-pyridyl)phenyl]-2-(methylamino)propanoate

[0205]

[0206] Step 1: Methyl (2S)-3-r5-chloro-2-(3-pyridyl)phenyl]-2-lmethyl-(2-nitrophenyl)sulfonyl-aminolpropanoate

[0207] To a light yellow solution of methyl (2S)-3-(2-bromo-5-chloro-phenyl)-2-[methyl-(2-nitrophenyl)sulfonyl-amino]propanoate (intermediate 7, step 4; 500 mg, 1.02 mmol) and pyridine-3-boronic acid (162 mg, 1.32 mmol) in 1,4-dioxane (10 mL) and water (1 mL) were added potassium carbonate (281 mg, 2.03 mmol) and l,l'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (83 mg, 0.1 mmol). The reaction mixture was heated at 100°C for 2 h, then partitioned between water (30 mL) and ethyl acetate (30 mL). The organic layer was dried over sodium sulfate, filtered, and evaporated. The residue was purified by preparative thin-layer chromatography (SiO₂; ethyl acetate / petroleum ether 5:1) to produce the title compound (400 mg, 79%). Light yellow oil, MS: 490.1 [M+H]+.

[0208] Step 2: Methyl -3-15-chloro-2- 3-pyridyl)phenyl1-2- methylamino)propanoate

[0209]

[0210] The title compound was produced in analogy to intermediate 7, step 7, from methyl (2S)-3-[5-chloro-2-(3-pyridyl)phenyl]-2-[methyl-(2-nitrophenyl)sulfonyl-amino]propanoate. Light yellow oil, MS: 305.1 [M+H]+.

[0211] Intermediate 13

[0212] Allyl (2S)-3-(4-iodophenyl)-2-(methylamino)propanoate

[0213]

[0214] Step 1: Allyl (2S)-2-(tert-butoxycarbonylamino)-3-(4-iodophenyl)propanoate

[0215] To a solution of N-tert-butoxycarbonyl-4-iodo-L-phenylalanine (CAS-RN 62129-44-6; 8.00 g, 20.5 mmol) and diisopropylethylamine (8.9 mL, 51.1 mmol) in N, N-dimethylformamide (100 mL) was added a solution of allyl bromide (3.53 mL, 40.9 mmol) in N, N-dimethylformamide (1 mL) at 0-5°C. The ice bath was removed, then after 16 h the reaction mixture was partitioned between water (100 mL) and ethyl acetate (100 mL). The organic layer was dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography (SiO₂; petroleum ether / ethyl acetate 5:1) to produce the title compound (7.9 g, 86%). White solid, MS: 453.9 [M+Na]+.

[0216] Step 2: Allyl (2S)-2-rtert-butoxycarbonyl(methyl)amino1-3-(4-iodophenyl)propanoate Silver(I) oxide (21.2 g, 91.6 mmol) and iodomethane (11.4 mL, 183 mmol) were added to a solution of allyl (2S)-2-(tert-butoxycarbonylamino)-3-(4-iodophenyl)propanoate (7.9 g, 18.3 mmol) in N, N-dimethylformamide (100 mL) at 25°C, then after 20 h the reaction mixture was partitioned between water (100 mL) and ethyl acetate (150 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated. The residue was purified by chromatography (SiO₂; petroleum ether / ethyl acetate 6:1) to produce the title compound (4.3 g, 47%).

[0217] Colourless oil, MS: 468.1 [M+H]+.

[0218] Step 3: Allyl (2S)-3-(4-iodophenyl)-2-(methylamino)propanoate

[0219] To a solution of allyl (2S)-2-[tert-butoxycarbonyl(methyl)amino]-3-(4-iodophenyl)propanoate (2.3 g, 5.17 mmol) in 1,4-dioxane (15 mL) was added hydrogen chloride solution (0.5 M in 1,4-dioxane, 20.4 mL, 10.4 mmol) at 25°C, then after 4 h the reaction mixture was concentrated. The residue was partitioned between saturated aq. sodium hydrogen carbonate solution and ethyl acetate. The organic layer was dried over sodium sulfate, filtered, and evaporated to produce the title compound (1.60 g, 83%). Colourless oil, MS: 346.0 [M+H],

[0220] Example 1

[0221] 4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[(3-iodophenyl)methyl]-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentazatricyclo[19.4.0.03’8]pentacosa-l(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid; dihydrochloride

[0222]

[0223] (tert-butoxycarbonylamino)-2-rr(2S)-5-(tert-butoxycarbonylamino)-2-(9H-fluoren-9-'

[0224]

[0225] methyl-

[0226]

[0227] To a light yellow solution of (2S)-6-(tert-butoxycarbonylamino)-2-[[(2S)-5-(tert-butoxycarbonylamino)-2-(9H-fluoren-9-ylmethoxycarbonylamino)pentanoyl]amino]hexanoic acid (CAS-RN 2971012-33-4; 899 mg, 1.32 mmol) in N, N-dimethylacetamide (8 mL) was added 1-hydroxy-7-azabenzotriazole (269 mg, 1.98 mmol) and N, N'-diisopropylcarbodiimide (0.52 mL, 3.29 mmol). The yellow solution was stirred at 0°C for 10 min, then treated with a solution of allyl (2S)-3-(3-iodophenyl)-2-(methylamino)propanoate (intermediate 2; 500 mg, 1.45 mmol) in N, N-dimethylacetamide (5 mL). The yellow solution was stirred at 25°C for 6 h, then partitioned between ethyl acetate (30 mL) and water (20 mL). The organic layer was washed with brine (30 mL), dried over sodium sulfate, filtered, and evaporated. The residue was purified by chromatography (SiO₂; petroleum ether – ethyl acetate gradient) to produce the title compound (870 mg, 65%). Brown oil, MS: 1010.7 [M+H]+.

[0228] 2: Allyl (2S)-2-IT(2S)-6-(tert-butoxycarbonylamino)-2-rr(2S)-5-(tert-butoxycarbonylamino)-2-(9H-fluoren-9-'

[0229]

[0230] methyl-

[0231]

[0232] To a solution of allyl (2S)-2-[[(2S)-6-(tert-butoxycarbonylamino)-2-[[(2S)-5-(tert-butoxycarbonylamino)-2-(9H-fluoren-9-ylmethoxycarbonylamino)pentanoyl]amino]hexanoyl]-methyl-amino]-3-(3-iodophenyl)propanoate (880 mg, 0.87 mmol) in acetonitrile (8 mL) was added diethylamine (0.9 mL, 8.7 mmol) at 25°C, then after 3 h the reaction mixture was concentrated under vacuum. The residue was purified by chromatography (SiO₂; dichloromethane – methanol gradient) to produce the title compound (600 mg, 88%). Light yellow oil, MS: 788.6 [M+H]+.

[0233]

[0234] i-2-allvloxv-l-r(3-i

[0235]

[0236] |-2-oxo- -

[0237]

[0238] To a suspension of allyl (2S)-2-[[(2S)-2-[[(2S)-2-amino-5-(tert-butoxycarbonylamino)- pentanoyl]amino]-6-(tert-butoxycarbonylamino)hexanoyl]-methyl-amino]-3-(3- iodophenyl)propanoate (600 mg, 0.76 mmol) and tert-butyl 4-[2-[(9H-fluoren-9- ylmethoxycarbonylamino)methyl]-3-[(3-formyl-2-pyridyl)sulfanyl]phenyl]benzoate (intermediate 1; 490 mg, 0.76 mmol) in toluene (8 mL), to the suspension was added acetic acid (0.09 mL, 1.5 mmol). The reaction mixture was stirred at 25°C, then after 1 h the reaction mixture was treated with sodium triacetoxyborohydride (291 mg, 1.37 mmol), then after another 16 h it was partitioned between ethyl acetate (20 mL) and brine (20 mL). The organic layer was dried over sodium sulfate, filtered, and evaporated. The residue was purified by chromatography (SiO₂; petroleum ether – ethyl acetate gradient) to produce the title compound (920 mg, 82%). Yellow oil, MS: 1414.9 [M+H]+.

[0239]

[0240] -6-(tert-

[0241]

[0242] acid

[0243] To a solution of tert-butyl 4-[3-[[3-[[[(l S)- 1 -[[(1 S)-l -[[(1 S)-2-allyloxy- 1 -[(3-iodophenyl)- methyl]-2-oxo-ethyl]-methyl-carbamoyl]-5-(tert-butoxycarbonylamino)pentyl]carbamoyl]-4- (tert-butoxycarbonylamino)butyl]amino]methyl]-2-pyridyl]sulfanyl]-2-[(9H-fluoren-9- ylmethoxycarbonylamino)methyl]phenyl]benzoate (920 mg, 0.65 mmol) in acetonitrile (10 mL) was added diethylamine (0.66 mL, 6.5 mmol) and tetrakis(triphenylphosphine)palladium(0) (75 mg, 0.07 mmol) at 25°C, then after 5 h the reaction mixture was concentrated. The residue was purified by chromatography (SiO₂; petroleum ether / ethyl acetate 1:1 to dichloromethane / methanol 4:1 gradient) to produce the title compound (800 mg, 81%). Yellow oil, MS: 1152.8 [M+H]+.

[0244]

[0245] To a solution of 1 -hydroxybenzotriazole hydrate (202 mg, 1.32 mmol) and l-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (253 mg, 1.32 mmol) indichloromethane (10 mL) was added a yellow solution of (2S)-2-[[(2S)-2-[[(2S)-2-[[2-[2-(aminomethyl)-3-(4-tert-butoxycarbonylphenyl)phenyl]sulfanyl-3-pyridyl]methylamino]-5-(tert-butoxycarbonylamino)pentanoyl]amino]-6-(tert-butoxycarbonylamino)hexanoyl]-methyl-amino]-3-(3-iodophenyl)propanoic acid (800 mg, 0.53 mmol) in dichloromethane (20 mL) at 0-5°C, then the solution was stirred at 25°C for 1 h, then evaporated. The residue was purified by preparative thin-layer chromatography (SiO₂; petroleum ether / ethyl acetate 1:1) to produce the title compound (300 mg, 43%). Light yellow solid, MS: 1134.4 [M+H]+.

[0246]

[0247] To a solution of tert-butyl 4-[(llS,14S,17S)-14-[4-(tert-butoxycarbonylamino)butyl]-ll-[3-(tert-butoxycarbonylamino)propyl]-17-[(3-iodophenyl)methyl]-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentazatricyclo[19.4.0.03’8]pentacosa-l(25),3(8),4,6,21,23-hexaen-22-yl]benzoate (65 mg, 0.06 mmol) in 1,4-di oxane (2 mL) was added hydrogen chloride solution (4 M in 1,4-dioxane, 3.0 mL, 12.0 mmol). After addition, the mixture was stirred at 40°C for 2 h, during which a precipitate formed. This precipitate was collected by filtration, washed with acetonitrile (3 mL), dissolved in water (20 mL) and lyophilized to produce the title compound (37 mg, 69%). White solid, MS: 878.5 [M+H]+.

[0248] The following examples (Ex.) were produced in analogy to example 1, replacing allyl (2S)-3-(3-iodophenyl)-2-(methylamino)propanoate in step 1 by the appropriate allyl ester.

[0249]

[0250]

[0251]

[0252]

[0253]

[0254] Example 124-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[(3-ethynylphenyl)methyl]-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentazatricyclo[19.4.0.03’8]pentacosa-l(21),3(8),4,6,22,24-hexaen-22-yl]benzoic acid; bis (2,2,2-trifluoroacetate)

[0255]

[0256] Step 1: tert-Butyl 4-r(llS,14S,17S)-14-r4-(tert-butoxycarbonylamino)butyl]-ll-r3-(tert-butoxycarbonylamino)propyl]- 16-m ethyl- 12,15,18-trioxo- 17-IT3 -(2-trimethylsilylethynyl)phenyl]methyl]-2-thia-4,10,13,16,19-pentazatricyclo|T9.4.0.03’8]pentacosa-1,3(8),4,6,21,23 -hexaen-22-yl]benzoate

[0257] To a solution of tert-butyl 4-[(llS,14S,17S)-14-[4-(tert-butoxycarbonylamino)butyl]-ll-[3-(tert-butoxycarbonylamino)propyl]-17-[(3-iodophenyl)methyl]-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentazatricyclo[19.4.0.03’8]pentacosa-l(25),3(8),4,6,21,23-hexaen-22-yl]benzoate (example 1, step 5; 100 mg, 0.09 mmol) and (trimethylsilyl)acetylene (865 mg, 8.8 mmol) in N, N-dimethylformamide (1 mL) was added triethylamine (0.12 mL, 0.88 mmol), bis(triphenylphosphine)palladium(II) (6.7 mg, 0.02 mmol) and copper(I) iodide (3.4 mg, 0.02 mmol) at 25°C, then after 15 h the reaction mixture was partitioned between ethyl acetate and brine. The organic layer was dried over sodium sulfate, filtered, and evaporated. The residue was purified by chromatography (SiCL; petroleum ether / ethyl acetate 3:1) to produce the title compound (100 mg, 96%). Light brown solid, MS: 1104.7 [M+H]+.

[0258] Step 2: 4-r(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-r(3-ethynylphenyl)methyl1-16-methyl- 12, 15,18-tri oxo-2 -thia-4,10,13, 16,19-pentazatricy clojl 9,4.0.03,81pentacosa-l(21),3(8),4,6,22,24-hexaen-22-yl]benzoic acid; bis (2,2,2-trifluoroacetate)

[0259] To a solution of tert-butyl 4-[(llS,14S,17S)-14-[4-(tert-butoxycarbonylamino)butyl]-ll-[3-(tert-butoxycarbonylamino)propyl]- 16-m ethyl- 12,15,18-trioxo- 17-[[3 -(2 -trimethyl silyl -ethynyl)phenyl]methyl]-2-thia-4,10,13,16,19-pentazatricyclo[19.4.0.03’8]pentacosa-l(25),3(8),4,6,21,23-hexaen-22-yl]benzoate (55 mg, 0.05 mmol) in dichloromethane (1 mL) was added trifluoroacetic acid (1.0 mL, 8.8 mmol) at 25°C, then after 2 h the reaction mixture wasevaporated. The residue was purified by preparative HPLC (Phenomenex Luna C18 150*40mm*15μm; gradient from 0.1% aq. trifluoroacetic acid solution to acetonitrile) to produce the title compound (31 mg, 61%). White solid, MS: 776.4 [M+H]+.

[0260] Example 13

[0261] 4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[(2-bromo-5-chloro-phenyl)methyl]-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentazatricyclo[19.4.0.03’8]pentacosa-l(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid; dihydrochloride

[0262]

[0263] Step 1: Allyl (2S)-3-(2-bromo-5-chloro-phenyl)-2-ll(2S)-6-(tert-butoxycarbonylamino)-2-ll(2S)-5-(tert-butoxycarbonylamino)-2-(9H-fluoren-9-ylmethoxy carbonylamino)-pentanoyl]amino]hexanoyl]-methyl-amino]propanoate

[0264] The title compound was produced in analogy to example 1, step 1, replacing allyl (2S)-3-(3-iodophenyl)-2-(methylamino)propanoate by allyl (2S)-3-(2-bromo-5-chloro-phenyl)-2-(methylamino)propanoate (intermediate 7). Light yellow solid, MS: 1019.8 [M+Na]+.

[0265] Step 2: Allyl (2S)-2-ll(2S)-2-ll(2S)-2-amino-5-(tert-butoxycarbonylamino)pentanoyl]amino]-6-(tert-butoxycarbonylamino)hexanoyl]-methyl-amino]-3-(2-bromo-5-chloro-phenyl)propanoate The title compound was produced in analogy to example 1, step 2, from allyl (2S)-3-(2-bromo-5-chloro-phenyl)-2-[[(2S)-6-(tert-butoxycarbonylamino)-2-[[(2S)-5-(tert-butoxycarbonylamino)-2-(9H-fluoren-9-ylmethoxycarbonylamino)pentanoyl]amino]hexanoyl]-methyl-amino]propanoate. Light yellow oil, MS: 776.4 [M+H]+.

[0266] Step 3: tert-Butyl 4-13-113-111(1 S)-l-ll(lS)-l-ll(lS)-2-allyloxy-l-l(2-bromo-5-chloro-phenyl)methyl]-2-oxo-ethyl]-methyl-carbamoyl]-5-(tert-butoxycarbonylamino)-pentyl]carbamoyl]-4-(tert-butoxycarbonylamino)butyl]amino]methyl]-2-pyridyl]sulfanyl]-2-l(9H-fluoren-9-ylmethoxycarbonylamino)methyl]phenyl]benzoateThe title compound was produced in analogy to example 1; step 3, from allyl (2S)-2-[[(2S)-2- [[(2S)-2-amino-5-(tert-butoxycarbonylamino)pentanoyl]amino]-6-(tert-butoxy carbonyl- amino)hexanoyl]-methyl-amino]-3-(2-bromo-5-chloro-phenyl)propanoate. Light yellow solid, MS: 1402.7 [M+H]+.

[0267]

[0268] -6-(tert-

[0269]

[0270] -methyl-amino]-3-(2-bromo-5-chloro-

[0271]

[0272] ic acid The title compound was produced in analogy to example 1; step 4, from tert-butyl 4-[3-[[3- [[[(lS)-l-[[(lS)-l-[[(lS)-2-allyloxy-l-[(2-bromo-5-chloro-phenyl)methyl]-2-oxo-ethyl]-methyl- carbamoyl]-5-(tert-butoxycarbonylamino)pentyl]carbamoyl]-4-(tert- butoxycarbonylamino)butyl]amino]methyl]-2-pyridyl]sulfanyl]-2-[(9H-fluoren-9- ylmethoxycarbonylamino)methyl]phenyl]benzoate. Light yellow solid, MS: 1140.4 [M+H]+.

[0273]

[0274] The title compound was produced in analogy to example 1, step 5, from (2S)-2-[[(2S)-2-[[(2S)- 2-[[2-[2-(aminomethyl)-3-(4-tert-butoxycarbonylphenyl)phenyl]sulfanyl-3- pyridyl]methylamino]-5-(tert-butoxycarbonylamino)pentanoyl]amino]-6-(tert- butoxycarbonylamino)hexanoyl]-methyl-amino]-3-(2-bromo-5-chloro-phenyl)propanoic acid. Light yellow solid, MS: 1121.7 [M+H]+.

[0275] i-17-l (2-bromo-5-chloro-

[0276]

[0277] n-22-yl]benzoic acid;

[0278] dihydrochloride

[0279] The title compound was produced in analogy to example 1, step 6, from tert-butyl 4- [(HS,14S,17S)-17-[(2-bromo-5-chloro-phenyl)methyl]-14-[4-(tert-butoxycarbonylamino)butyl]- 11 -[3 -(tert-butoxycarbonylamino)propyl]- 16-methyl- 12,15,18-trioxo-2-thia-4, 10,13,16,19- pentazatricyclo[19.4.0.03’8]pentacosa-l(25),3(8),4,6,21,23-hexaen-22-yl]benzoate. Light yellow solid, MS: 866.4 [M+H]+.

[0280] Example 144-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[[2-(4-carboxyphenyl)-5-chloro-phenyl]methyl]-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentazatricyclo[19.4.0.03’8]pentacosa-l(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid;

[0281] dihydrochloride

[0282]

[0283] To a solution of tert-butyl 4-[(llS,14S,17S)-17-[(2-bromo-5-chloro-phenyl)methyl]-14-[4-(tert-butoxycarbonylamino)butyl]-ll-[3-(tert-butoxycarbonylamino)propyl]-16-methyl-12,15,18-trioxo-2-thia-4, 10,13,16,19-pentazatricyclo[ 19.4.0.03,8]pentacosa- 1 (25), 3 (8), 4, 6, 21,23 -hexaen-22-yl]benzoate (example 13, step 5; 100 mg, 0.09 mmol) and 4-(tert-butoxycarbonyl)phenylboronic acid (29.7 mg, 0.13 mmol) in toluene (5 mL) and water (0.5 mL) was added tripotassium phosphate (37.8 mg, 0.18 mmol) and bis(tri-tert-butylphosphine)palladium(O) (4.6 mg, 0.01 mmol) in the glovebox at 20°C, then the mixture was stirred at 80 °C for 5 h. After cooling the reaction mixture was partitioned between ethyl acetate (10 mL) and water (3 mL). The organic layer was washed with brine, dried over sodium sulfate, filtered, and evaporated. The residue was purified by preparative HPLC (Phenomenex Luna C18 150*40mm*15μm; gradient from 0.05% aq. formic acid solution to acetonitrile) to produce the title compound (40 mg, 36%). Light yellow solid, MS: 1218.6 [M+H]+.

[0284] i-5-

[0285]

[0286] dihydrochlorideThe title compound was produced in analogy to example 1, step 6, from tert-butyl 4-[(HS,14S,17S)-14-[4-(tert-butoxycarbonylamino)butyl]-ll-[3-(tert-butoxycarbonyl-amino)propyl]-17-[[2-(4-tert-butoxycarbonylphenyl)-5-chloro-phenyl]methyl]-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentazatricyclo[19.4.0.03’8]pentacosa-l(25),3(8),4,6,21,23-hexaen-22-yl]benzoate. White solid, MS: 906.3 [M+H]+.

[0287] The following examples (Ex.) were produced in analogy to example 14, replacing 4-(tert-butoxycarbonyl)phenylboronic acid in step 1 by the appropriate boronic acid.

[0288]

[0289]

[0290]

[0291]

[0292] Example 21

[0293] 4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[[5-chloro-2-(2-hydroxyphenyl)phenyl]methyl]-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentazatricyclo[19.4.0.03’8]pentacosa-l(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid; dihydrochloride

[0294]

[0295] Step 1: tert-Butyl 4-r(llS,14S,17S)-14-r4-(tert-butoxycarbonylamino)butyl1-ll-r3-(tert-butoxycarbonylamino)propyl]-17- chloro-2-(2-methoxyphenyl)phenyl]methyl]-16-methyl-

[0296]

[0297] 12,15,18-trioxo-2-thia-4,10,13,16,19-pentazatricyclori9.4.0.03’8]pentacosa-l(25),3(8),4,6,21,23-hexaen-22-yl]benzoateThe title compound was produced in analogy to example 14, step 1, from tert-butyl 4-[(HS,14S,17S)-17-[(2-bromo-5-chloro-phenyl)methyl]-14-[4-(tert-butoxycarbonylamino)butyl]-11 -[3 -(tert-butoxycarbonylamino)propyl]- 16-m ethyl- 12,15,18-trioxo-2-thia-4, 10,13,16,19-pentazatricyclo[19.4.0.03’8]pentacosa-l(25),3(8),4,6,21,23-hexaen-22-yl]benzoate (example 13, step 5) and 2-methoxyphenylboronic acid. Light yellow solid, MS: 1148.6 [M+H]+.

[0298] 2-(2-

[0299]

[0300] acid;

[0301] dihydrochloride

[0302] To a solution of tert-butyl 4-[(llS,14S,17S)-14-[4-(tert-butoxycarbonylamino)butyl]-ll-[3-(tert-butoxycarbonylamino)propyl]-17-[[5-chloro-2-(2-methoxyphenyl)phenyl]methyl]-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentazatricyclo[19.4.0.03’8]pentacosa-l(25),3(8),4,6,21,23-hexaen-22-yl]benzoate (100 mg, 0.09 mmol) in dichloromethane (2 mL) was added boron tribromide solution (2 M in dichloromethane; 2.0 mL, 4.0 mmol) dropwise at 0°C, then the mixture was stirred at 20°C for 2 h. After 2 h the reaction mixture was evaporated and the residue was purified by preparative HPLC (Phenomenex Gemini Cl 8, 150*25mm*10 pm; gradient from 0.05 aq. hydrochloric acid solution to acetonitrile) to produce the title compound (29 mg, 35%). Light yellow solid, MS: 878.4 [M+H]+.

[0303] Example 22

[0304] 4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[[5-chloro-2-(2-pyridyl)phenyl]methyl]-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentazatricyclo[19.4.0.03’8]pentacosa-l(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid;

[0305] dihydrochloride

[0306]

[0307] 1-1 l-[3-(tert- |-17-|T5-chloro-2-(2- |-16-methyl-12, 15,18-.4.0.03’8]pentacosa-l(25),3(8),4,6,21,23-hexaen-

[0308]

[0309] To a solution of tert-butyl 4-[(llS,14S,17S)-17-[(2-bromo-5-chloro-phenyl)methyl]-14-[4-(tert- butoxycarbonylamino)butyl]-ll-[3-(tert-butoxycarbonylamino)propyl]-16-methyl-12,15,18- trioxo-2-thia-4, 10,13,16,19-pentazatricyclo[ 19.4.0.03,8]pentacosa- 1 (25), 3 (8), 4, 6, 21,23 -hexaen- 22-yl]benzoate (example 13, step 5; 200 mg, 0.18 mmol) and sodium pyridine-2-sulfmate (CAS- RN 24367-66-6; 117.79 mg, 0.71 mmol) in dimethyl sulfoxide (3 mL) and toluene (3 mL) were added potassium carbonate (73.9 mg, 0.53 mmol) and palladium(II) acetate (20 mg, 0.09 mmol). The reaction mixture was heated at 130°C for 16 h, then evaporated. The residue was purified by preparative HPLC ((Phenomenex Luna Cl 8 150*40mm*15pm; gradient from 0.05% aq. trifluoroacetic acid solution to acetonitrile) to produce the title compound (40 mg, 18%). Light yellow solid, MS: 1118.9 [M+H],

[0310] -chloro-2-(2-

[0311]

[0312] benzoic acid;

[0313] dihydrochloride

[0314] The title compound was produced in analogy to example 1, step 6, from tert-butyl 4- [(HS,14S,17S)-14-[4-(tert-butoxycarbonylamino)butyl]-ll-[3-(tert- butoxycarbonylamino)propyl]-17-[[5-chloro-2-(2-pyridyl)phenyl]methyl]-16-methyl-12,15,18- trioxo-2-thia-4, 10,13,16,19-pentazatricyclo[ 19.4.0.03,8]pentacosa- 1 (25), 3 (8), 4, 6, 21,23 -hexaen- 22-yl]benzoate. Light yellow solid, MS: 863.2 [M+H]+.

[0315] Example 23

[0316] 4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[[5-chloro-2-(3- pyridyl)phenyl]methyl]-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19- pentazatricyclo[19.4.0.03’8]pentacosa-l(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid;

[0317] dihydrochloride

[0318]

[0319] 6-(tert-butoxvcarbonylamino)-2-|

[0320]

[0321] i-5-(tert- butoxycarbonylamino)-2-(9H-fluoren-9-

[0322]

[0323] methyl- -3-r5-chloro-2-(3-

[0324]

[0325] The title compound was produced in analogy to example 1, step 1, replacing allyl (2S)-3-(3- iodophenyl)-2-(methylamino)propanoate by methyl (2S)-3-[5-chloro-2-(3-pyridyl)phenyl]-2- (methylamino)propanoate (intermediate 12). Light yellow oil, MS: 969.5 [M+H]+.

[0326]

[0327] -methyl-amino]-3-r5-chloro-2-(3-

[0328]

[0329] The title compound was produced in analogy to example 1, step 2, from methyl (2S)-2-[[(2S)-6- (tert-butoxycarbonylamino)-2-[[(2S)-5-(tert-butoxycarbonylamino)-2-(9H-fluoren-9- ylmethoxycarbonylamino)pentanoyl]amino]hexanoyl]-methyl-amino]-3-[5-chloro-2-(3- pyridyl)phenyl]propanoate Light yellow oil, MS: 747.7 [M+H]+.

[0330]

[0331] i-4-(tert-butoxycarbonylamino)- 1 -I

[0332]

[0333] i-5-ftert- butoxycarbonylamino)- 1 -I

[0334]

[0335] i-l-ir5-chloro-2-(3-

[0336]

[0337] -2-methoxy-2-oxo-

[0338]

[0339] The title compound was produced in analogy to example 1, step 3, from methyl (2S)-2-[[(2S)-2- [[(2S)-2-amino-5-(tert-butoxycarbonylamino)pentanoyl]amino]-6-(tert- butoxycarbonylamino)hexanoyl]-methyl-amino]-3-[5-chloro-2-(3-pyridyl)phenyl]propanoate and tert-butyl 4-[2-[(9H-fluoren-9-ylmethoxycarbonylamino)methyl]-3-[(3-formyl-2- pyridyl)sulfanyl]phenyl]benzoate (intermediate 1). Light yellow solid, MS: 1374.2 [M+H]+. Step 4: -2-rr2-r2- Aminomethyl -3- 4-tert-

[0340]

[0341] -3-1 -5 -(tert-|-methyl-

[0342]

[0343] To a solution of tert-butyl 4-[3-[[3-[[[(lS)-4-(tert-butoxycarbonylamino)-l-[[(lS)-5-(tert- butoxycarbonylamino)-l-[[(lS)-l-[[5-chloro-2-(3-pyridyl)phenyl]methyl]-2-methoxy-2-oxo- ethyl]-methyl-carbamoyl]pentyl]carbamoyl]butyl]amino]methyl]-2-pyridyl]sulfanyl]-2-[(9H- fluoren-9-ylmethoxycarbonylamino)methyl]phenyl]benzoate (300 mg, 0.22 mmol) in acetonitrile (5 mL) were added diethylamine (0.22 mL, 2.18 mmol) and lithium bromide (190 mg, 2.18 mmol) at 25°C. The reaction mixture was heated at 40°C for 4 h, then evaporated. The residue was purified by chromatography (SiO2; dichloromethane / methanol 10:1) to produce the title compound (300 mg, 74%). Light yellow solid, MS: 1138.0 [M+H]+.

[0344]

[0345] The title compound was produced in analogy to example 1, step 5, from (2S)-2-[[(2S)-2-[[(2S)- 2-[[2-[2-(aminomethyl)-3-(4-tert-butoxycarbonylphenyl)phenyl]sulfanyl-3- pyridyl]methylamino]-5-(tert-butoxycarbonylamino)pentanoyl]amino]-6-(tert- butoxycarbonylamino)hexanoyl]-methyl-amino]-3-[5-chloro-2-(3-pyridyl)phenyl]propanoic acid. White solid, MS: 1119.4 [M+H]+.

[0346] -chloro-2-(3-

[0347]

[0348] benzoic acid;

[0349] dihydrochloride

[0350] The title compound was produced in analogy to example 1, step 6, from tert-butyl 4- [(HS,14S,17S)-14-[4-(tert-butoxycarbonylamino)butyl]-ll-[3-(tert- butoxycarbonylamino)propyl]-17-[[5-chloro-2-(3-pyridyl)phenyl]methyl]-16-methyl-12,15,18- trioxo-2-thia-4, 10,13,16,19-pentazatricyclo[ 19.4.0.03,8]pentacosa- 1 (25), 3 (8), 4, 6, 21,23 -hexaen- 22-yl]benzoate. Light yellow solid, MS: 863.4 [M+H]+.

[0351] Example 24

[0352] Antimicrobial susceptibility testing: 50% Growth Inhibitory Concentration (IC50) determinationThe in vitro antimicrobial activity of the compounds was alternatively determined according to the following procedure:

[0353] The assay used a 10-points Iso-Sensitest broth medium to measure quantitatively the in vitro activity of the compounds against baumannii ATCC 17961.

[0354] Stock compounds in DMSO were serially twofold diluted (e.g. range from 50 to 0.097 pM or from 10 to 0.020 pM final concentration) in 384 wells microtiter plates and inoculated with 49 pl the bacterial suspension in Iso-Sensitest medium to have a final cell concentration of- 5xl0(5)CFU / ml in a final volume / well of 50 pl / well. Microtiter plates were incubated at 35 ± 2 °C.

[0355] Bacterial cell growth was determined with the measurement of optical density at k=600 nm each 20 minutes over a time course of 16 h.

[0356] Growth inhibition was calculated during the logarithmic growth of the bacterial cells with determination of the concentration inhibiting 50% (IC50) of the growth.

[0357] Table 1 provides the 50% growth inhibitory concentrations (IC50) in micromoles per liter of the compounds of present invention obtained against the A. baumannii strain ATCC 17961.

[0358] In one embodiment, compounds of the present invention exhibit an IC50 (ATCC17961) < 10 pmol / 1.

[0359] In a preferred embodiment, compounds of the present invention exhibit an IC50 (ATCC 17961) < 1 pmol / 1.

[0360] In a particularly preferred embodiment, compounds of the present invention exhibit an IC50 (ATCC17961) < 0.5 pmol / 1.

[0361]

[0362]

[0363] Table 1. 50% growth inhibition concentrations (IC50) in micromoles per liter of the compounds of present invention obtained against baumannii strain ATCC 17961.

Claims

Claims1. A compound of formula (I)or a pharmaceutically acceptable salt thereof, wherein:Y is CH or N;m is an integer selected from the group consisting of 1, 2, and 3;n is an integer selected from the group consisting of 1, 2, and 3;R1, R2, and R3are each independently selected from the group consisting of hydrogen, halogen, cyano, C1-6-alkyl, C2-6-alkynyl, C6-10-aryl, 5- to 14-membered heteroaryl, and 3- to 14-membered heterocycloalkyl; wherein said C6-10-aryl and 5- to 14- membered heteroaryl are optionally substituted with 1-3 substituents independently selected from the group consisting of hydroxy, halogen, cyano, C1-6-alkyl, Ci-6-aloxy, and carboxy; and wherein said 3- to 14-membered heterocycloalkyl is optionally substituted with 1-3 substituents independently selected from the group consisting of oxo, hydroxy, halogen, cyano, C1-6-alkyl, Ci-6-aloxy, and carboxy; andR4is selected from the group consisting of hydrogen, halogen, C1-6-alkyl, and halo-Ci-6- alkyl;wherein said heteroaryl and said heterocycloalkyl comprise 1-4 heteroatoms selected from N, O and S, the remaining ring atoms being carbon.

2. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is a compound of formula (la):wherein the variables are as defined in claim 1.

3. The compound of formula (I) according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein m is 2 and n is 3.

4. The compound of formula (I) according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein Y is N.

5. The compound of formula (I) according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is a compound of formula (lb):wherein the variables are as defined in claim 1.

6. The compound of formula (I) according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein:R1is selected from the group consisting of hydrogen, halogen, cyano, C1-6-alkyl, C2-6- alkynyl, C6-10-aryl, 5- to 14-membered heteroaryl, and 3- to 14-membered heterocycloalkyl; wherein said C6-10-aryl and 5- to 14-membered heteroaryl are optionally substituted with 1-3 substituents independently selected from the group consisting of hydroxy, halogen, cyano, C1-6-alkyl, Ci-6-aloxy, and carboxy; and wherein said 3- to 14-membered heterocycloalkyl is optionally substituted with 1-3 substituents independently selected from the group consisting of oxo, hydroxy, halogen, cyano, C1-6-alkyl, Ci-6-aloxy, and carboxy;R2is selected from the group consisting of hydrogen, halogen, and C1-6-alkyl; and R3is selected from the group consisting of hydrogen and halogen.

7. The compound of formula (I) according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein:R1is selected from the group consisting of hydrogen, halogen, C1-6-alkyl, C2-6-alkynyl, C6-10-aryl, 5- to 14-membered heteroaryl, and 3- to 14-membered heterocycloalkyl; wherein said C6-10-aryl is optionally substituted with 1 substituent selected from the group consisting of hydroxy, Ci-6-aloxy, and carboxy; and wherein said 3- to 14- membered heterocycloalkyl is substituted with oxo and optionally 1 C1-6-alkyl substituent;R2is selected from the group consisting of hydrogen, halogen, and C1-6-alkyl; and R3is selected from the group consisting of hydrogen and halogen.

8. The compound of formula (I) according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein:R1is selected from the group consisting of hydrogen, fluoro, chloro, iodo, methyl, ethynyl, phenyl, pyridyl, and 1,2-dihydropyridyl; wherein said phenyl is optionally substituted with 1 substituent selected from the group consisting of hydroxy, methoxy, and carboxy; and wherein said 1,2-dihydropyridyl is substituted with oxo and optionally 1 methyl substituent;R2is selected from the group consisting of hydrogen, fluoro, chloro, iodo, and methyl;andR3is selected from the group consisting of hydrogen, fluoro, chloro, and iodo.

9. The compound of formula (I) according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein:R1is selected from the group consisting of halogen, C1-6-alkyl, and C6-10-aryl;R2is selected from the group consisting of hydrogen and halogen; andR3is hydrogen.

10. The compound of formula (I) according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein:R1is selected from the group consisting of iodo, methyl, and phenyl;R2is selected from the group consisting of hydrogen and iodo; andR3is hydrogen.

11. The compound of formula (I) according to any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein R4is hydrogen.

12. The compound of formula (I) according to claim 1, selected from the group consisting of:4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[(3-iodophenyl)methyl]-16- methyl-12, 15,18-trioxo-2-thia-4,l 0,13, 16,19-pentazatricy clo[l 9.4.0.03,8]pentacosa- 1 (25), 3 (8), 4, 6, 21,23 -hexaen-22-yl]benzoic acid;4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-benzyl-16-methyl-12,15,18- trioxo-2-thia-4, 10, 13, 16,19-pentazatricy clo[l 9.4.0.03,8]pentacosa-l (25), 3(8), 4, 6, 21,23- hexaen-22-yl]benzoic acid;4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[(3-bromophenyl)methyl]- 16-methyl-12, 15,18-trioxo-2-thia-4,l 0,13, 16,19-pentazatricy clo[l 9.4.0.03,8]pentacosa- 1 (25), 3 (8), 4, 6, 21,23 -hexaen-22-yl]benzoic acid;4-[(l lS,14S,17S)-14-(4-Aminobutyl)-l l-(3-aminopropyl)-17-[(5-chloro-2-methyl- phenyl)methyl]- 16-methyl- 12,15,18-trioxo-2-thia-4, 10,13,16,19- pentazatricyclof 19.4.0.03,8]pentacosa- 1 (25), 3 (8), 4, 6, 21,23 -hexaen-22-yl]benzoic acid; 4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[(3-chlorophenyl)methyl]- 16-methyl-12, 15,18-trioxo-2-thia-4,l 0,13, 16,19-pentazatricy clo[l 9.4.0.03,8]pentacosa- 1 (25), 3 (8), 4, 6, 21,23 -hexaen-22-yl]benzoic acid;4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[(2-iodophenyl)methyl]-16- methyl-12, 15,18-trioxo-2-thia-4,l 0,13, 16,19-pentazatricy clo[l 9.4.0.03,8]pentacosa- 1 (25), 3 (8), 4, 6, 21,23 -hexaen-22-yl]benzoic acid;4-[( 11 S, 14S, 17 S)- 14-(4- Aminobutyl)- 11 -(3 -aminopropyl)- 17-[(5-iodo-2-phenyl- phenyl)methyl]- 16-methyl- 12,15,18-trioxo-2-thia-4, 10,13,16,19- pentazatricyclof 19.4.0.03,8]pentacosa- 1 (25), 3 (8), 4, 6, 21,23 -hexaen-22-yl]benzoic acid;4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[(5-iodo-2,4-dimethyl- phenyl)methyl]- 16-methyl- 12,15,18-trioxo-2-thia-4, 10,13,16,19- pentazatricyclof 19.4.0.03,8]pentacosa- 1 (25), 3 (8), 4, 6, 21,23 -hexaen-22-yl]benzoic acid; 4-[( 11 S, 14 S, 17 S)- 14-(4- Aminobutyl)- 11 -(3 -aminopropyl)- 17- [(4-fluoro-3 -iodo- phenyl)methyl]- 16-methyl- 12,15,18-trioxo-2-thia-4, 10,13,16,19- pentazatricyclo[19.4.0.03’8]pentacosa-l(21),3(8),4,6,22,24-hexaen-22-yl]benzoic acid; 4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[(5-iodo-2-methyl- phenyl)methyl]- 16-methyl- 12,15,18-trioxo-2-thia-4, 10,13,16,19- pentazatricyclo[19.4.0.03’8]pentacosa-l(21),3(8),4,6,22,24-hexaen-22-yl]benzoic acid; 4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[(4-iodophenyl)methyl]-16- methyl-12, 15,18-trioxo-2-thia-4,l 0,13, 16,19-pentazatricy clo[l 9.4.0.03,8]pentacosa- 1 (25), 3 (8), 4, 6, 21,23 -hexaen-22-yl]benzoic acid;4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[(3-ethynylphenyl)methyl]- 16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentazatricyclo[19.4.0.03’8]pentacosa- l(21),3(8),4,6,22,24-hexaen-22-yl]benzoic acid;4-[(l lS,14S,17S)-14-(4-Aminobutyl)-l l-(3-aminopropyl)-17-[(2-bromo-5-chloro- phenyl)methyl]- 16-methyl- 12,15,18-trioxo-2-thia-4, 10,13,16,19- pentazatricyclof 19.4.0.03,8]pentacosa- 1 (25), 3 (8), 4, 6, 21,23 -hexaen-22-yl]benzoic acid; 4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[[2-(4-carboxyphenyl)-5- chloro-phenyl]methyl]-l 6-methyl-12, 15,18-trioxo-2-thia-4, 10,13,16,19- pentazatricyclof 19.4.0.03,8]pentacosa- 1 (25), 3 (8), 4, 6, 21,23 -hexaen-22-yl]benzoic acid; 4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[(5-chloro-2-phenyl- phenyl)methyl]- 16-methyl- 12,15,18-trioxo-2-thia-4, 10,13,16,19- pentazatricyclof 19.4.0.03,8]pentacosa- 1 (25), 3 (8), 4, 6, 21,23 -hexaen-22-yl]benzoic acid; 3 - [2- [ [( 11 S, 14 S, 17 S)- 14-(4- Aminobutyl)- 11 -(3 -aminopropyl)-22-(4-carboxyphenyl)- 16- methyl-12, 15,18-trioxo-2-thia-4,l 0,13, 16,19-pentazatricy clo[l 9.4.0.03,8]pentacosa- 1 (25), 3 (8), 4, 6, 21,23 -hexaen- 17-yl]methyl]-4-chloro-phenyl]benzoic acid;4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[[5-chloro-2-(2- methoxyphenyl)phenyl]methyl]- 16-methyl- 12,15,18-trioxo-2-thia-4, 10,13,16,19- pentazatricyclof 19.4.0.03,8]pentacosa- 1 (25), 3 (8), 4, 6, 21,23 -hexaen-22-yl]benzoic acid; 4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[[5-chloro-2-(4- pyridyl)phenyl]methyl]- 16-methyl- 12,15,18-trioxo-2-thia-4, 10,13,16,19- pentazatricyclof 19.4.0.03,8]pentacosa- 1 (25), 3 (8), 4, 6, 21,23 -hexaen-22-yl]benzoic acid;4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[[5-chloro-2-(2-oxo-lH- pyridin-3-yl)phenyl]methyl]-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19- pentazatricyclof 19.4.0.03,8]pentacosa- 1 (25), 3 (8), 4, 6, 21,23 -hexaen-22-yl]benzoic acid; 4-[(l lS,14S,17S)-14-(4-Aminobutyl)-l l-(3-aminopropyl)-17-[[5-chloro-2-(l-methyl-2- oxo-3 -pyridyl)phenyl]methyl]- 16-methyl- 12,15,18-trioxo-2-thia-4, 10,13,16,19- pentazatricyclof 19.4.0.03,8]pentacosa- 1 (25), 3 (8), 4, 6, 21,23 -hexaen-22-yl]benzoic acid; 4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[[5-chloro-2-(2- hydroxyphenyl)phenyl]methyl]- 16-methyl- 12,15,18-trioxo-2-thia-4, 10,13,16,19- pentazatricyclof 19.4.0.03,8]pentacosa- 1 (25), 3 (8), 4, 6, 21,23 -hexaen-22-yl]benzoic acid; 4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[[5-chloro-2-(2- pyridyl)phenyl]methyl]- 16-methyl- 12,15,18-trioxo-2-thia-4, 10,13,16,19- pentazatricyclof 19.4.0.03,8]pentacosa- 1 (25), 3 (8), 4, 6, 21,23 -hexaen-22-yl]benzoic acid; and4-[(llS,14S,17S)-14-(4-Aminobutyl)-ll-(3-aminopropyl)-17-[[5-chloro-2-(3- pyridyl)phenyl]methyl]- 16-methyl- 12,15,18-trioxo-2-thia-4, 10,13,16,19- pentazatricyclof 19.4.0.03,8]pentacosa- 1 (25), 3 (8), 4, 6, 21,23 -hexaen-22-yl]benzoic acid; or a pharmaceutically acceptable salt thereof.

13. A pharmaceutical composition comprising a compound according to any of claims 1 to 12, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

14. A compound according to any of claims 1 to 12, or a pharmaceutically acceptable salt thereof, for use as therapeutically active substance.

15. A compound according to any of claims 1 to 12, or a pharmaceutically acceptable salt thereof, for use as an antibiotic.***